Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Normal circulating serum amyloid P component concentration in systemic sclerosis.

Glenys A Tennent1, Magdalena Dziadzio, Eva Triantafillidou

  • 1Centre for Amyloidosis and Acute Phase Proteins, Department of Medicine, University College London, London, UK. g.tennents@medsch.ucl.ac.uk

Arthritis and Rheumatism
|May 29, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Expert recommendations for the management of fecal incontinence in systemic sclerosis: A report from the World Scleroderma Foundation (WSF) Gastrointestinal "Ad hoc committee".

Journal of scleroderma and related disorders·2026
Same author

Expert recommendations for the management of refractory gastroesophageal reflux disease in systemic sclerosis: A report from the World Scleroderma Foundation (WSF) Gastrointestinal "Ad hoc committee".

Journal of scleroderma and related disorders·2026
Same author

Real-World Safety and Effectiveness of JAK Inhibitors in Systemic Sclerosis: A Propensity-Matched Study From the EUSTAR Cohort.

Arthritis care & research·2026
Same author

Influence of comorbidities and patient demographics on Raynaud's symptom characteristics: implications for diagnosis and management.

Journal of scleroderma and related disorders·2026
Same author

Measuring disease activity in juvenile systemic sclerosis: a multidisciplinary consensus from the Hamburg 2024 symposium.

Expert review of clinical immunology·2026
Same author

Pulmonary arterial hypertension susceptibility and mortality among patients with systemic sclerosis with the DNASE1L3 rs35677470 (Arg206Cys) variant.

Annals of the rheumatic diseases·2026
Same journal

Proceedings of the Annual Meeting of the American Rheumatism Association.

Arthritis and rheumatism·2020
Same journal

The regional distribution of rheumatologists: what can we do, what should we do?

Arthritis and rheumatism·2013
Same journal

Regional distribution of adult rheumatologists.

Arthritis and rheumatism·2013
Same journal

Clinically significant renal involvement in primary Sjögren's syndrome: clinical presentation and outcome.

Arthritis and rheumatism·2013
Same journal

Headache in systemic lupus erythematosus: results from a prospective, international inception cohort study.

Arthritis and rheumatism·2013
Same journal

Association of low baseline levels of erythrocyte folate with treatment nonresponse at three months in rheumatoid arthritis patients receiving methotrexate.

Arthritis and rheumatism·2013
See all related articles

Serum amyloid P component (SAP) levels were normal in systemic sclerosis (SSc) patients, refuting claims of its antifibrotic role. This study found no association between SAP concentrations and SSc fibrosis extent or severity.

Area of Science:

  • Biochemistry
  • Immunology
  • Rheumatology

Background:

  • Previous studies suggested serum amyloid P component (SAP) has an antifibrotic role in systemic sclerosis (SSc).
  • This suggestion was based on observations of reduced SAP concentrations in a small cohort of SSc patients.
  • However, sustained SAP depletion in humans and SAP deficiency in mice do not correlate with fibrosis.

Purpose of the Study:

  • To rigorously investigate serum SAP concentrations in well-characterized patients with systemic sclerosis (SSc).
  • To determine if SAP levels correlate with the extent and severity of fibrosis in SSc.
  • To challenge the previously reported antifibrotic role of SAP in SSc.

Main Methods:

  • Serum SAP concentrations were measured using electroimmunoassay in cross-sectional and longitudinal cohorts of SSc patients.

Related Experiment Videos

  • Disease extent and severity were meticulously characterized at the time of serum sampling.
  • Serum concentrations of acute-phase reactants (C-reactive protein, serum amyloid A protein) were also measured.

    • Main Results:

    • Serum SAP values were consistently within the normal range for all SSc patients studied.
    • No correlation was found between SAP levels and the extent or severity of SSc fibrosis.
    • Isolated elevated SAP values were linked to acute intercurrent complications causing major acute-phase responses.

    Conclusions:

    • This study found no evidence of reduced circulating SAP concentrations in patients with SSc.
    • The findings do not support an association between SAP levels and the extent or severity of fibrosis in SSc.
    • The proposed antifibrotic role of SAP in SSc is not substantiated by this rigorous investigation.